Shareholders Approve New Equity Incentive Plan Authorizing 350K Shares, Plus Annual 5% Evergreen Provision
ERNA sits 95% above its 52-week low of $3.183.
Summary
Ernexa Therapeutics shareholders approved a new equity incentive plan, reserving 350,000 shares and including an annual 5% evergreen provision, which could lead to significant dilution for existing shareholders.
Key Events · Financing and Capital Events · ERNA
-
Equity Incentive Plan Approved
Shareholders approved the 2026 Omnibus Equity Incentive Plan at the Annual Meeting held on July 1, 2026. This follows a DEF 14A filing on May 11, 2026, which proposed the plan.
-
Significant Initial Share Reserve
The plan initially reserves 350,000 shares for awards. Based on 1,166,333 shares outstanding as of May 6, 2026 (post-reverse split), this represents a potential dilution of approximately 30%.
-
Annual Evergreen Provision
The plan includes an evergreen provision, automatically increasing the share reserve by 5% of outstanding common stock each January 1st from 2027 through 2036, adding to long-term dilutive potential.
-
Routine Annual Meeting Outcomes
Shareholders also elected five directors and ratified Haskell & White LLP as the independent registered public accounting firm for 2026.
Analysis · ERNA · Life Sciences
Shareholders approved the 2026 Omnibus Equity Incentive Plan, which initially reserves 350,000 shares for awards. This represents a significant potential dilution of approximately 30% based on the 1,166,333 shares outstanding as of May 6, 2026. Furthermore, the plan includes an 'evergreen' provision that will automatically increase the share reserve by 5% of outstanding common stock annually for the next decade. While equity incentive plans are standard for attracting and retaining talent, this level of potential dilution is substantial for a micro-cap company facing ongoing going concern doubts, as noted in previous financial filings.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1075 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ERNA was trading at $6.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $3.18 to $71.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.